Our findings demonstrated that CXCL14 knockdown in CAFs significantly enhanced tumor sensitivity to cisplatin, an effect that was also observed in the CCR7i and STAT3i groups (Fig. 5I and Fig. S5G). The gene discussed is CXCL14; the disease is neoplasm.